NCT04330638View on ClinicalTrials.gov

Treatment of COVID-19 Patients With Anti-interleukin Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

December 20, 2020

Study Completion Date

May 21, 2021

Conditions
COVID-19
Interventions
OTHER

Usual Care

Usual Care

DRUG

Anakinra

Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first

DRUG

Siltuximab

Siltuximab will be given via single IV infusion at a dose of 11 mg/kg

DRUG

Tocilizumab

Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection

Trial Locations (15)

1000

University Hospital Saint-Pierre, Brussels

1070

Erasmus University Hospital, Brussels

1090

University Hospital Brussels, Jette

1200

University Hospital Saint-Luc, Brussels

1340

Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve

2650

University Hospital Antwerp, Edegem

3500

Jessa ZH, Hasselt

3600

Ziekenhuis Oost-Limurg, Genk

4000

CHR de la Citadelle, Liège

University Hospital Liège, Liège

7100

CHU Tivoli, La Louvière

8000

AZ Sint-Jan Brugge, Bruges

8800

AZ Delta, Roeselare

9000

AZ Sint-Lucas, Ghent

University Hospital Ghent, Ghent

All Listed Sponsors
collaborator

Belgium Health Care Knowledge Centre

OTHER_GOV

lead

University Hospital, Ghent

OTHER

NCT04330638 - Treatment of COVID-19 Patients With Anti-interleukin Drugs | Biotech Hunter | Biotech Hunter